Leerink Partnrs Has Bullish Outlook for NRIX FY2025 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for Nurix Therapeutics in a report issued on Wednesday, October 22nd. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings of ($3.05) per share for the year, up from their prior estimate of ($3.33). The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q4 2025 earnings at ($0.81) EPS, Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.87) EPS and FY2026 earnings at ($3.20) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, October 9th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). The business had revenue of $7.89 million during the quarter, compared to the consensus estimate of $16.06 million. Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.

Other equities research analysts also recently issued reports about the company. Wells Fargo & Company decreased their target price on Nurix Therapeutics from $22.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday. Wall Street Zen downgraded Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, October 11th. Stephens reissued an “overweight” rating and set a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, July 10th. HC Wainwright reissued a “buy” rating and set a $33.00 target price on shares of Nurix Therapeutics in a research report on Monday, October 20th. Finally, Mizuho initiated coverage on Nurix Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $24.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.07.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $11.09 on Monday. The business’s 50-day simple moving average is $9.49 and its 200-day simple moving average is $10.54. The firm has a market capitalization of $852.60 million, a PE ratio of -3.73 and a beta of 2.33. Nurix Therapeutics has a 52 week low of $8.18 and a 52 week high of $29.56.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NRIX. Tower Research Capital LLC TRC raised its stake in shares of Nurix Therapeutics by 118.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after acquiring an additional 3,475 shares during the last quarter. Velan Capital Investment Management LP bought a new position in shares of Nurix Therapeutics in the second quarter valued at approximately $114,000. E Fund Management Co. Ltd. bought a new position in shares of Nurix Therapeutics in the first quarter valued at approximately $122,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Nurix Therapeutics in the 2nd quarter worth approximately $141,000. Finally, Sei Investments Co. acquired a new position in Nurix Therapeutics during the 2nd quarter worth $158,000.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 5,402 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the transaction, the chief financial officer owned 35,512 shares in the company, valued at approximately $391,697.36. The trade was a 13.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gwenn Hansen sold 4,308 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,739.08. Following the completion of the transaction, the insider owned 69,023 shares of the company’s stock, valued at $828,966.23. This trade represents a 5.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,014 shares of company stock worth $163,014 over the last ninety days. Company insiders own 7.40% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.